Vera Therapeutics Expands Atacicept Autoimmune Kidney Studies
Company Announcements

Vera Therapeutics Expands Atacicept Autoimmune Kidney Studies

Vera Therapeutics ( (VERA) ) has provided an update.

Vera Therapeutics, Inc., a biotech firm focused on immunological diseases, has announced the expansion of its atacicept development program. The program will now include two new studies, ORIGIN Extend and PIONEER, targeting multiple autoimmune kidney diseases. Atacicept, designed to inhibit key factors in B-cell activation, has shown positive results in treating IgAN and is expected to enter extended trials and target a broader range of autoimmune diseases. This expansion could significantly change the treatment landscape for patients with autoimmune kidney conditions.

See more data about VERA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyVera Therapeutics partners with University of Michigan on NEPTUNE match project
TipRanks Auto-Generated NewsdeskVera Therapeutics Advances in Autoimmune Treatment
TheFlyVera Therapeutics reports Q3 EPS (85c), consensus (66c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App